Semaglutide and tirzepatide are both GLP-1 class medications used for medical weight loss — but they work differently, perform differently in clinical trials, and may be appropriate for different patients. Here's what Arizona patients need to know before asking their provider about either option.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist — a medication that mimics the GLP-1 hormone that your gut naturally releases after eating. By activating GLP-1 receptors in the brain, pancreas, and gut, semaglutide tells the body it's full, slows gastric emptying (the rate at which food moves through the stomach), and reduces appetite signals.
The brand-name versions are Ozempic (approved for Type 2 diabetes) and Wegovy (approved for chronic weight management). Compounded semaglutide is also available through licensed compounding pharmacies, though it is not FDA-approved as a finished product.
In the landmark STEP 1 clinical trial (published in the New England Journal of Medicine, 2021), participants using semaglutide lost an average of 14.9% of body weight over 68 weeks. That is a clinically meaningful result — meaningful enough to have transformed medical weight loss practice globally.
What Is Tirzepatide?
Tirzepatide is newer — and more powerful. It targets two hormone receptors: GLP-1 (same as semaglutide) and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism gives it a more complex effect on appetite, insulin secretion, and fat metabolism.
Brand names include Mounjaro (approved for Type 2 diabetes) and Zepbound (approved for chronic weight management). Compounded tirzepatide is also available through licensed pharmacies.
In the SURMOUNT-1 trial (also published in the NEJM, 2022), participants on the highest tirzepatide dose lost an average of 22.5% of body weight — the largest weight loss ever recorded for a pharmaceutical treatment. This made tirzepatide the most clinically impactful weight loss medication ever studied.
Key Differences: A Side-by-Side View
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual agonist |
| Average weight loss (clinical trials) | ~15–20% | ~20–22.5% |
| Dosing frequency | Once weekly injection | Once weekly injection |
| FDA approval (weight) | Wegovy (weight), Ozempic (diabetes) | Zepbound (weight), Mounjaro (diabetes) |
| Side effect profile | Nausea, GI effects — generally well tolerated | Similar GI effects — may differ by individual |
| Provider determines fit | Based on health history, goals, BMI | Based on health history, goals, BMI |
Which Is Right for Arizona Patients?
The honest answer: only a licensed provider can determine which medication is appropriate for a specific patient. Several factors influence this decision:
Medical history — Contraindications differ slightly between medications. Your provider needs a complete health history before recommending either.
Weight loss goals — Patients with more weight to lose or who have struggled significantly with prior treatments may be stronger candidates for tirzepatide's more robust mechanism.
Side effect tolerance — Individual response to GI side effects varies. Starting with semaglutide and switching if needed is a reasonable approach for some patients.
Cost — At Arizona Trim Clinic: Semaglutide from $149/month · Tirzepatide from $169/month. No membership fee · No contract · No annual commitment · No required prepayment · Free shipping · Free consultation. Your exact price depends on your prescribed dose. Your provider confirms it before you pay.
Results vary. Medical eligibility required. This article is for educational purposes only and does not constitute medical advice. Speak with a licensed provider to determine if treatment is right for you.